# Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct03136484` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03136484](<https://clinicaltrials.gov/study/NCT03136484>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03136484

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 788 participants.

## Technical summary

Registry record NCT03136484. Randomized; double masking; primary purpose treatment. Start 2017-03-15 (actual); primary completion 2018-10-16 (actual). Results posted on 2019-12-17.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 788 participants (enrolled count; ClinicalTrials.gov record NCT03136484, source copy `cardio:ctgov-nct03136484-2020-01-21`, retrieved 2026-10-26)
- Started: 2017-03-15 (actual) (ClinicalTrials.gov record NCT03136484, source copy `cardio:ctgov-nct03136484-2020-01-21`, retrieved 2026-10-26)
- Primary completion: 2018-10-16 (actual) (ClinicalTrials.gov record NCT03136484, source copy `cardio:ctgov-nct03136484-2020-01-21`, retrieved 2026-10-26)
- Completion: 2018-11-16 (actual) (ClinicalTrials.gov record NCT03136484, source copy `cardio:ctgov-nct03136484-2020-01-21`, retrieved 2026-10-26)
- Results first posted: 2019-12-17 (ClinicalTrials.gov record NCT03136484, source copy `cardio:ctgov-nct03136484-2020-01-21`, retrieved 2026-10-26)
- Countries: United States; Argentina; Brazil; Canada; India; Ireland; Italy; Lebanon; Malaysia; Mexico; Sweden; United Kingdom (ClinicalTrials.gov record NCT03136484, source copy `cardio:ctgov-nct03136484-2020-01-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03136484-2020-01-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
- Acronym: SUSTAIN 8
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Semaglutide
- Intervention (Drug): Canagliflozin
- Intervention (Drug): Placebo (canagliflozin)
- Intervention (Drug): Placebo (semaglutide)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial (`cardio:pubmed-31540867`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial (`cardio:pubmed-31897524`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 8608262651f7d39e006b5afba7bd50acfb9b2e2fa66f1b69084c9699fa4683f4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
